Talk:List of therapeutic monoclonal antibodies

This is the talk page for discussing improvements to the List of therapeutic monoclonal antibodies article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL

Lists

	This article is within the scope of WikiProject Lists, an attempt to structure and organize all list pages on Wikipedia. If you wish to help, please visit the project page, where you can join the project and/or contribute to the discussion.ListsWikipedia:WikiProject ListsTemplate:WikiProject ListsList articles
???	This article has not yet received a rating on the project's importance scale.

Pharmacology High‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
High	This article has been rated as High-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about List of therapeutic monoclonal antibodies.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Untitled

Subpages: Hoaxes

I've seen someone put Campath in my list, or efalizumab will block the T cell migration. --BlakeCS 07:20, 26 January 2007 (UTC)[reply]

Purpose

Let's see if I can expand this whole list as I can. Right? --Blake3522 14:11, 8 July 2007 (UTC)[reply]

OK. I can get this higher than 10KB. --Blake3522 06:23, 15 July 2007 (UTC)[reply]

Deleted

All hoaxes were deleted per Wikipedia:Articles for deletion/Ananeuzumab. --202.67.104.55 (talk) 12:47, 25 December 2007 (UTC)[reply]

Hoax warning

Unfortunately, Blake3522 and BlakeCL created dozens and dozens of bogus stubs. It may well be that not all have been deleted, or that some redlinks here relate to bogus articles. Someone knowledgeable needs to check.--Scott MacDonald (talk) 23:42, 4 October 2008 (UTC)[reply]

As mentioned in the section above, or in the subpage. --58.178.193.122 (talk) 06:19, 10 October 2008 (UTC)[reply]

As of January 2010, all redlinks in this list have been checked and sourced. --ἀνυπόδητος (talk) 13:33, 15 January 2010 (UTC)[reply]

Proposal to create additional column "Action"

This column would be placed after "Target" (before "Use") and there would likely be 2 or 3 target types, possibly receptor inhibitor, mab inhibitor, or mab analogue. (I don't know this area well but I think this extra column would be really informative). Mangofast (talk) 11:08, 15 March 2016 (UTC)[reply]

Rules for new entries

Some antibodies appear as separate entries, even though they correspond to the same compound ( Lambrolizumab, Pembrolizumab ) and the linked wikipedia page refers to them as being the same. On the other hand for historic reasons they may be considered separate products. Presently it is not clear under which conditions separate entries should be kept. Tsttsttsttst (talk) 19:30, 21 March 2017 (UTC)[reply]

I'd say they are synonyms of the same substance, so they shouldn't have separate entries in the list just as they don't have separate articles. I have removed the lambrolizumab row. Thanks for catching this. --ἀνυπόδητος (talk) 07:44, 22 March 2017 (UTC)[reply]